Payment overview · 2025
General Payments
$2,440.89
113 reported records · 40 companies
Healthcare provider profile · identity verified
Bethany King, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · DAPHNE, AL · NPI 1497301139
Verified facts
What the public records show
CMS Open Payments records show Bethany King, CRNP received $2,440.89 in general payments during 2025 across 113 reported records.
Novartis Pharmaceuticals Corporation accounted for 10.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 71 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brukinsa.
BeOne Medicines USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 10251 records involving 4941 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brukinsa by this doctor in 2024.
BeiGene USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 2084 records involving 1673 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brukinsa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $261.52 | 10.7% | 13 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $253.89 | 10.4% | 7 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $220.93 | 9.1% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $176.65 | 7.2% | 8 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $151.02 | 6.2% | 9 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $111.47 | 4.6% | 5 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $101.79 | 4.2% | 3 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $95.11 | 3.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $84.86 | 3.5% | 5 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $84.47 | 3.5% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $72.46 | 3.0% | 4 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $72.33 | 3.0% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $62.27 | 2.5% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $52.39 | 2.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.59 | 1.9% | 2 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.58 | 1.9% | 2 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $41.95 | 1.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.80 | 1.6% | 2 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $36.04 | 1.5% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $33.61 | 1.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $30.40 | 1.2% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.52 | 1.1% | 1 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.75 | 1.0% | 1 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.62 | 1.0% | 1 | 2025 |
| IMMUNITYBIO, INC. | Unresolved — no canonical attribution shown | $23.91 | 1.0% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $23.65 | 1.0% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $23.08 | 0.9% | 1 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $20.32 | 0.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.76 | 0.8% | 1 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $19.27 | 0.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.15 | 0.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.46 | 0.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.63 | 0.7% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.87 | 0.7% | 1 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $15.60 | 0.6% | 1 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $15.01 | 0.6% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $14.53 | 0.6% | 1 | 2025 |
| Myriad Genetic Laboratories, Inc. | Unresolved — no canonical attribution shown | $14.10 | 0.6% | 1 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $13.92 | 0.6% | 2 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $13.61 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,440.89 | 113 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc., BeiGene USA, Inc. | $249.12 | 8 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation, Merck Sharp & Dohme LLC | $194.91 | 7 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $149.94 | 7 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $103.10 | 5 | 2025 |
Source payment records
|
|||||
| Zoladex Normalized: zoladex |
Drug | TerSera Therapeutics LLC | $101.79 | 3 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $95.11 | 4 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $84.47 | 3 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $82.58 | 5 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $82.58 | 5 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $82.13 | 4 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $78.97 | 3 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $68.41 | 3 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $65.05 | 3 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $62.27 | 3 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $56.65 | 3 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $55.73 | 3 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $52.39 | 3 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $51.26 | 3 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $49.49 | 3 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $48.57 | 2 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $47.59 | 2 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $47.58 | 2 | 2025 |
Source payment records
|
|||||
| ROMVIMZA Normalized: romvimza |
Drug | Deciphera Pharmaceuticals Inc. | $47.58 | 2 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $45.29 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $43.77 | 3 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.71 | 2 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.71 | 2 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $41.95 | 2 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological | Merck Sharp & Dohme LLC | $38.91 | 2 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $34.94 | 2 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $34.94 | 2 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $33.50 | 2 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | Sumitomo Pharma America, Inc. | $30.40 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $25.52 | 1 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| ANKTIVA Normalized: anktiva |
Drug | IMMUNITYBIO, INC. | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| ZIIHERA Normalized: ziihera |
Drug | JAZZ PHARMACEUTICALS INC. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| POMALYST Normalized: pomalyst |
Drug | Celgene Corporation | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| RETEVMO Normalized: retevmo |
Drug | Lilly USA, LLC | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| Columvi Normalized: columvi |
Biological | Genentech USA, Inc. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| Lunsumio Normalized: lunsumio |
Biological | Genentech USA, Inc. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Hybreza Normalized: tecentriq hybreza |
Biological | Genentech USA, Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| Optune Lua (NovoTTF-200T) Normalized: optune lua novottf 200t |
Device | Novocure Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| MYRISK Normalized: myrisk |
Device | Myriad Genetic Laboratories, Inc. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRUKINSA brukinsa |
2025 | Brukinsa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| BeOne Medicines USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 10251 supporting records · 4941 recipient NPIs · example record 1202883638 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| BeiGene USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 2084 supporting records · 1673 recipient NPIs · example record 1202877750 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 90 | 57 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 30 | 14 |
| Letrozole | Letrozole | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 22 | 14 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | 11 |
| Brukinsa | Zanubrutinib | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,440.89 · 113 records | Novartis Pharmaceuticals Corporation | AKEEGA, ANKTIVA, BALVERSA, BRAFTOVI, BRUKINSA, CALQUENCE, Columvi, DANZITEN, DARZALEX, DATROWAY, ELAHERE, ENHERTU, ERLEADA, FOTIVDA, Fabhalta, IBRANCE, IMFINZI, INQOVI, Itovebi, JAKAFI, JAYPIRCA, JEMPERLI, KEYTRUDA, KISQALI, LIBTAYO, LONSURF, LORBRENA, LYNPARZA, Lenvima, Lunsumio, MEKTOVI, MI CANCER SEEK, MONJUVI, MONOFERRIC, MYRISK, NERLYNX, NINLARO, Nubeqa, OJJAARA, OPDIVO, ORGOVYX, Optune Lua (NovoTTF-200T), Orserdu, PLUVICTO, POMALYST, Polivy, QINLOCK, REBLOZYL, RETEVMO, ROMVIMZA, RYBREVANT, SARCLISA, SCEMBLIX, Stivarga, TALVEY, TEVIMBRA, TUKYSA, Tecentriq, Tecentriq Hybreza, ULTOMIRIS, VERZENIO, Vitrakvi, WAYRILZ, WELIREG, XPOVIO, Xofigo, Yescarta, ZIIHERA, ZYNYZ, Zoladex, clonoSEQ | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brukinsa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with BeOne Medicines USA, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error